Ademi LLP Investigates Soleno for Possible Fiduciary Breaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLNO?
Source: PRnewswire
- Transaction Investigation: Ademi LLP is investigating Soleno's transaction with Neurocrine for potential breaches of fiduciary duty and legal violations, with a total transaction equity value of $2.9 billion, offering shareholders $53.00 per share.
- Restrictive Competition Clauses: The transaction agreement imposes unreasonable restrictions, including significant penalties for accepting competing bids, which may harm shareholder interests and affect market competition.
- Board Accountability: The investigation focuses on whether Soleno's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring fairness and transparency in the transaction to protect shareholder rights.
- Shareholder Litigation Expertise: Ademi LLP specializes in litigation involving buyouts, mergers, and individual shareholder rights, aiming to safeguard shareholders' legal rights and ensure compliance in corporate governance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.490
Low
75.00
Averages
110.50
High
125.00
Current: 39.490
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Fluctuate Slightly Amid Ceasefire Talks and Falling Oil Prices
- Market Movements: The S&P 500 Index rose by 0.19%, while the Dow Jones Industrial Average dipped by 0.04%, and the Nasdaq 100 Index increased by 0.50%, indicating slight fluctuations in the market amid strong economic data, reflecting cautious optimism among investors regarding future economic prospects.
- Strong Employment Data: March nonfarm payrolls surged by 178,000, significantly exceeding expectations of 65,000, and the unemployment rate unexpectedly fell by 0.1% to 4.3%, demonstrating resilience in the U.S. labor market, which may positively influence market sentiment.
- Declining Oil Prices: Crude oil prices fell by over 1% amid ceasefire negotiations in the Iran conflict, which could affect energy market stability; the International Energy Agency warned that even if the war ends, it will take time for normal flows through the Strait of Hormuz to resume, impacting global supply chains.
- Tech Stock Performance: Chipmakers and AI infrastructure stocks are climbing, with Seagate Technology's stock rising over 7%, showcasing ongoing market confidence in the tech sector, which may drive further investment and innovation in related companies.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Soleno Therapeutics for violations of securities laws, concerning securities transactions between March 26, 2025, and November 4, 2025, with a deadline for participation set for May 5, 2026.
- False Statement Allegations: The complaint alleges that Soleno misled the market regarding safety issues in its DCCR clinical trial, resulting in investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Concealed Safety Risks: Soleno's DCCR treatment exhibited greater safety risks than disclosed, along with lower commercial viability and increased adverse event risks, leading to direct financial losses for investors due to the lack of transparency.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and to seek compensation for their losses.
See More
Ademi LLP Investigates Soleno for Possible Fiduciary Breaches
- Transaction Investigation: Ademi LLP is investigating Soleno's transaction with Neurocrine for potential breaches of fiduciary duty and legal violations, with a total transaction equity value of $2.9 billion, offering shareholders $53.00 per share.
- Restrictive Competition Clauses: The transaction agreement imposes unreasonable restrictions, including significant penalties for accepting competing bids, which may harm shareholder interests and affect market competition.
- Board Accountability: The investigation focuses on whether Soleno's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring fairness and transparency in the transaction to protect shareholder rights.
- Shareholder Litigation Expertise: Ademi LLP specializes in litigation involving buyouts, mergers, and individual shareholder rights, aiming to safeguard shareholders' legal rights and ensure compliance in corporate governance.
See More
Soleno Therapeutics Soars 26% on Acquisition Talks with Neurocrine Biosciences
- Acquisition Talks Progress: Neurocrine Biosciences is in advanced discussions to acquire Soleno Therapeutics, with the deal potentially valued at over $2.5 billion, leading to a 26% surge in premarket trading, reflecting strong market optimism about the transaction.
- Market Opportunity: Should the acquisition proceed, Neurocrine would gain access to Soleno's treatment for Prader-Willi syndrome, which analysts project could generate up to $2.3 billion in peak annual sales, enhancing the strategic appeal of the acquisition.
- Price Target Analysis: The anticipated acquisition price is in the range of $50 to $60 per share, indicating investor confidence in Soleno's future growth potential while providing Neurocrine with an opportunity to enter new markets.
- Warning Signals: Despite the stock surge, GuruFocus has flagged 4 warning signs for Soleno, advising investors to cautiously assess its true value to avoid potential investment risks.
See More
Class Action Filed Against Soleno Therapeutics Over DCCR Disclosures
- Lawsuit Background: A securities class action has been filed against Soleno Therapeutics (NASDAQ: SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a disappointing report on DCCR (trademarked as VYKAT™ XR) released on November 5, 2025.
- Stock Price Plunge: The report triggered a 26% drop in Soleno's stock price on the day of release, reflecting strong market concerns about the company's future commercial prospects and prompting Hagens Berman to investigate potential violations of federal securities laws.
- Safety Concerns: The lawsuit alleges that Soleno systematically downplayed and concealed significant safety risks associated with DCCR, including issues of fluid retention in clinical trial participants, which could materially diminish the drug's commercial viability.
- Eroded Market Confidence: Since August 15, 2025, Soleno's stock has fallen nearly 40%, with management acknowledging during the Q3 2025 earnings call that the short seller's report significantly disrupted their launch trajectory, further undermining investor confidence in the company's future.
See More
Neurocrine Acquires Soleno for $2.9 Billion to Expand Rare Disease Portfolio
- Acquisition Overview: Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for approximately $2.9 billion, aiming to expand its market presence in rare diseases and endocrinology, highlighting the company's strategic focus on this sector.
- Share Price Premium: The acquisition values Soleno shares at $53 each, representing a notable 34% premium over Friday's closing price, reflecting positive market expectations and recognition of Soleno's future potential.
- Therapy Integration: The acquisition centers on Soleno's therapy VYKAT XR (diazoxide choline), which targets hyperphagia associated with Prader-Willi syndrome, expected to enhance Neurocrine's product offerings in this therapeutic area.
- Market Reaction: Following the announcement, Soleno Therapeutics' stock traded over 39% higher in Monday's premarket, indicating strong investor response and optimism regarding the company's future prospects post-acquisition.
See More
US Stocks Fluctuate Slightly Amid Ceasefire Talks and Falling Oil Prices
- Market Movements: The S&P 500 Index rose by 0.19%, while the Dow Jones Industrial Average dipped by 0.04%, and the Nasdaq 100 Index increased by 0.50%, indicating slight fluctuations in the market amid strong economic data, reflecting cautious optimism among investors regarding future economic prospects.
- Strong Employment Data: March nonfarm payrolls surged by 178,000, significantly exceeding expectations of 65,000, and the unemployment rate unexpectedly fell by 0.1% to 4.3%, demonstrating resilience in the U.S. labor market, which may positively influence market sentiment.
- Declining Oil Prices: Crude oil prices fell by over 1% amid ceasefire negotiations in the Iran conflict, which could affect energy market stability; the International Energy Agency warned that even if the war ends, it will take time for normal flows through the Strait of Hormuz to resume, impacting global supply chains.
- Tech Stock Performance: Chipmakers and AI infrastructure stocks are climbing, with Seagate Technology's stock rising over 7%, showcasing ongoing market confidence in the tech sector, which may drive further investment and innovation in related companies.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Soleno Therapeutics for violations of securities laws, concerning securities transactions between March 26, 2025, and November 4, 2025, with a deadline for participation set for May 5, 2026.
- False Statement Allegations: The complaint alleges that Soleno misled the market regarding safety issues in its DCCR clinical trial, resulting in investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Concealed Safety Risks: Soleno's DCCR treatment exhibited greater safety risks than disclosed, along with lower commercial viability and increased adverse event risks, leading to direct financial losses for investors due to the lack of transparency.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to take action before class certification to ensure their rights are protected and to seek compensation for their losses.
See More
Ademi LLP Investigates Soleno for Possible Fiduciary Breaches
- Transaction Investigation: Ademi LLP is investigating Soleno's transaction with Neurocrine for potential breaches of fiduciary duty and legal violations, with a total transaction equity value of $2.9 billion, offering shareholders $53.00 per share.
- Restrictive Competition Clauses: The transaction agreement imposes unreasonable restrictions, including significant penalties for accepting competing bids, which may harm shareholder interests and affect market competition.
- Board Accountability: The investigation focuses on whether Soleno's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring fairness and transparency in the transaction to protect shareholder rights.
- Shareholder Litigation Expertise: Ademi LLP specializes in litigation involving buyouts, mergers, and individual shareholder rights, aiming to safeguard shareholders' legal rights and ensure compliance in corporate governance.
See More
Soleno Therapeutics Soars 26% on Acquisition Talks with Neurocrine Biosciences
- Acquisition Talks Progress: Neurocrine Biosciences is in advanced discussions to acquire Soleno Therapeutics, with the deal potentially valued at over $2.5 billion, leading to a 26% surge in premarket trading, reflecting strong market optimism about the transaction.
- Market Opportunity: Should the acquisition proceed, Neurocrine would gain access to Soleno's treatment for Prader-Willi syndrome, which analysts project could generate up to $2.3 billion in peak annual sales, enhancing the strategic appeal of the acquisition.
- Price Target Analysis: The anticipated acquisition price is in the range of $50 to $60 per share, indicating investor confidence in Soleno's future growth potential while providing Neurocrine with an opportunity to enter new markets.
- Warning Signals: Despite the stock surge, GuruFocus has flagged 4 warning signs for Soleno, advising investors to cautiously assess its true value to avoid potential investment risks.
See More
Class Action Filed Against Soleno Therapeutics Over DCCR Disclosures
- Lawsuit Background: A securities class action has been filed against Soleno Therapeutics (NASDAQ: SLNO) to represent investors who purchased common stock between March 26 and November 4, 2025, following a disappointing report on DCCR (trademarked as VYKAT™ XR) released on November 5, 2025.
- Stock Price Plunge: The report triggered a 26% drop in Soleno's stock price on the day of release, reflecting strong market concerns about the company's future commercial prospects and prompting Hagens Berman to investigate potential violations of federal securities laws.
- Safety Concerns: The lawsuit alleges that Soleno systematically downplayed and concealed significant safety risks associated with DCCR, including issues of fluid retention in clinical trial participants, which could materially diminish the drug's commercial viability.
- Eroded Market Confidence: Since August 15, 2025, Soleno's stock has fallen nearly 40%, with management acknowledging during the Q3 2025 earnings call that the short seller's report significantly disrupted their launch trajectory, further undermining investor confidence in the company's future.
See More
Neurocrine Acquires Soleno for $2.9 Billion to Expand Rare Disease Portfolio
- Acquisition Overview: Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for approximately $2.9 billion, aiming to expand its market presence in rare diseases and endocrinology, highlighting the company's strategic focus on this sector.
- Share Price Premium: The acquisition values Soleno shares at $53 each, representing a notable 34% premium over Friday's closing price, reflecting positive market expectations and recognition of Soleno's future potential.
- Therapy Integration: The acquisition centers on Soleno's therapy VYKAT XR (diazoxide choline), which targets hyperphagia associated with Prader-Willi syndrome, expected to enhance Neurocrine's product offerings in this therapeutic area.
- Market Reaction: Following the announcement, Soleno Therapeutics' stock traded over 39% higher in Monday's premarket, indicating strong investor response and optimism regarding the company's future prospects post-acquisition.
See More
